Owning your premises is still a great option
The Scottish Intercollegiate Guidelines Network moved closer to a 4mmol/l total cholesterol target after agreeing it would be clinically effective.
SIGN is to examine the cost-effectiveness of lowering the cholesterol target for secondary prevention of CHD
after a 'positive response' to its draft proposals at a meeting in Edinburgh this week.
NICE said it would consider the SIGN guidance in its own review of statins use, but would not confirm whether it would take the same view.
Dr James Grant, chair of the SIGN CHD prevention guideline group, said: 'This is a target we believe evidence supports for secondary prevention and not for primary prevention. That was in general positively received by the meeting.'
Dr Grant, a GP in Auchterader, Perthshire, added: 'To do this would involve the prescribing of a large amount of statins and other drugs, with obvious cost issues.'
SIGN released draft guidance recommending the 4mmol/l target in August and plans to release final guidance next spring, following findings from a newly commissioned cost-effectiveness analysis.